Swedish Orphan Biovitrum AB · OMXSTO:SOBI
Swedish Orphan Biovitrum AB — Q3 2010 Earnings Presentation
13 slides from Swedish Orphan Biovitrum AB's earnings presentation, Oct 26, 2010
Slide 1: Third Quarter 2010
Third Quarter 2010 2010-10-26
Slide 2: Disclaimer
DISCLAIMER In order to utilize the ‘Safe Harbor’ provisions of the United States Private Securities Litigation Reform Act of 1995, Swedish Orphan Biovitrum is providing the following cautionary statement. This presentation contains forward- looking statements with respect to the financial condition,
Slide 3: Q3 2010 – Weak European performance, offset by continued US sales growth
Q3 2010 – Weak European performance, offset by continued US sales growth • Revenues, excluding Tracleer, increased by 5% in Constant Exchange Rate (CER), (unchanged in SEK) • North American sales increased by 16% in CER (17% in SEK) • European sales decreased by 1% in CER (-10% in SEK) • Nordic sale
Slide 4: January 1 to September 30, 2010
January 1 to September 30, 2010 • Revenues, excluding Tracleer, increased by 4% in Constant Exchange Rate (CER), (-2% in SEK) • North American sales increased by 22% in CER (15% in SEK) • European sales increased by 5% in CER (-5% in SEK) • Nordic sales, excluding Tracleer, increased by 10% in CER (
Slide 5: Revenues by product
Revenues by product Jul 1 - Sep 30 Jan 1 - Sep 30 CER CER CER CER Amounts in SEK million 2010 2010 2009 change 2010 2010 2009 Change ReFacto® 124.9 129.9 124.9 4% 429.7 440.9 495.4 -11% of which Manufacturing revenues 77.3 77.3 63.2 22% 268.2 268.2 294.9 -9% of which Co-promotion 23.8 24.9 19.5 28%
Slide 6: Product revenues by region
Product revenues by region (excl. ReFacto manufacturing and royalty) Jul 1 - Sep 30 Jan 1 - Sep 30 CER CER CER CER Amounts in SEK million 2010 2010 2009 Change 2010 2010 2009 Change Nordic 112.5 118.1 127.0 -7% 347.5 363.9 381.6 -5% Europe 125.6 138.7 139.9 -1% 410.8 453.8 431.6 5% North America 97.
Slide 7: Important R&D events and business deals in Q3 2010 and after the period
Important R&D events and business deals in Q3 2010 and after the period • A Letter of Intent to form a commercial alliance with the Chinese company Dongbao was announced • rFIXFc phase I/II results, showing a three-fold increase in half-life, were presented • A decision to proceed rFVIIIFc into phas
Slide 8: Full year guidance has been adjusted
Full year guidance has been adjusted • While US sales grows was strong, sales in Europe has been weaker than expected • European countries are facing budget troubles • In particular, manifested during the second half of the third quarter • Mandatory price cuts or discounts • Risk adverse buying patt
Slide 9: New Outlook 2010 – Long term objectives unchanged
New Outlook 2010 Long term objectives unchanged • Revenues, excluding milestone revenues, expected to reach 1,900-1,950 MSEK, corresponding to a growth of 1-4% in CER • Previous guidance 8-10% in CER • Operating income, before amortizations and restructuring costs (EBITA*) is expected to be 240-260
Slide 10: Exciting and emerging development pipeline
Exciting and emerging development pipeline Indication Product/Project Preclinical Phase I Phase II Phase III Reg phase Hemophilia A rFVIIIFc Hemophilia B rFIXFc Fat malabsorption in premature infants Kiobrina® CAPS Kineret® Rh-Immunization Sym001 Autoimmune platelet disorder (ITP) Sym001 10
Slide 11: Development news flow
Development news flow Activity Expected timing rFVIIIFc (hemophilia A): start dosing phase III H2 2010 Kiobrina (fat malarbsorption): start dosing phase III H1 2011 Sym001 (ITP): report phase II study H2 2011 rFIXFc (hemophilia B): report phase III 2012 11
Slide 12: Summary
Summary • Revenues in the quarter increased by 5% in CER • Weak European sales performance, in particular during the second half of the quarter • Continued North American and Orfadin sales growth • Positive progress of the hemophilia projects • Letter of Intent to form a commercial alliance formed w
Slide 13: www.sobi.com
@sobdl SWEDISH ORPHAN BIOVITRUM www.sobi.com 2010-10-26
Swedish Orphan Biovitrum — Q3 2010 Earnings Presentation on 6ix